Rhythm Pharmaceuticals (RYTM) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rhythm Pharmaceuticals (RYTM) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 10.4% versus a loss of 38.5%. Over five years, RYTM leads with a +1116.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RYTM | SMMT |
|---|---|---|
| Share price | $112.36 | $9.95 |
| Market cap | $7.79B | $7.96B |
| 1-day change | -3.80% | -5.87% |
| YTD return | +4.97% | -43.11% |
| 1-year return | +10.44% | -38.54% |
| 5-year return | +1116.02% | +92.83% |
| EPS (TTM) | $-2.91 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $189.76M | — |
| Revenue growth (YoY) | +45.83% | — |
| Net income (latest FY) | $-196.54M | $-1.08B |
| Gross margin | 89.73% | — |
| Operating margin | -101.19% | — |
| Net margin | -103.57% | — |
| 52-week high | $122.20 | $29.23 |
| 52-week low | $74.50 | $9.89 |
| Distance from 52-week high | -8.05% | -65.96% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +24.71% | +189.15% |
| Average volume | 1.10M | 6.68M |
| Shares outstanding | 69.33M | 799.76M |
| Employees | 414 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RYTM has outperformed SMMT by 49.0 percentage points over the past year.
About Rhythm Pharmaceuticals
RYTM stock →Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
RYTM vs SMMT FAQ
Which is bigger, Rhythm Pharmaceuticals or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).
Which stock has performed better over the past year, RYTM or SMMT?
RYTM returned +10.44% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Rhythm Pharmaceuticals and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.